Podcast Leading Beyond The Lab par ARTO Talent Épisodes

Explorez tous les épisodes du podcast Leading Beyond The Lab

Plongez dans la liste complète des épisodes de Leading Beyond The Lab. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.

	Titre	Date	Durée
	Behzad Kharabi: Biotech Executive, Clinical Development, Hematology & Oncology	07 Feb 2025	00:34:18
In this Episode, our guest is Dr. Behzad Kharabi, a consultant and CMO of multiple biotechs. At present, Dr Kharabi is the Medical Advisor at MaaT Pharma, the leading microbiome company in oncology, and has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Behzad is also the CMO at Tigen, a clinical-stage biotech company in the field of cell therapies to cure cancer.. Dr. Kharabi has founded his own clinical consulting company - Kharabi Consulting, aiming to provide the highest quality of clinical development support. We discuss Behzad’s profound career beginnings, and then move into topics around becoming a successful biotech and the key lessons Behzad learnt to get to where he is today. Dr. Kharabi unveils a mix of stories and insights, including discussions about biotech success and failure, communicating with investors, recruitment in life sciences, how AI is being using in drug development, recent oncology discovery and more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Youtube: ARTO Recruitment Website: Home Dr. Behzad Kharabi LinkedIn: https://www.linkedin.com/in/behzadkharabi/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 12:08 Advice for Moving Into Industry 16:38 Key Learnings for Leaders 29:41 AI’s Future in Drug Development #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Hematology Hosted on Acast. See acast.com/privacy for more information.
	Antonella Chadha: Founder @ Women's Brain Foundation, TED Speaker, Medical Doctor and Neuroscientist	14 Feb 2025	00:50:56
In this episode, our guest is Dr. Antonella Santuccione Chadha, globally recognised founder of the Women’s Brain Foundation, TED speaker, medical doctor and neuroscientist. Dr. Chadha is also a fractional CMO in Neurology & Medtech, as well as an Advisor to ReconnectLAB, Bottneuro, and EQUAL CARE. We discuss how Antonella paved her way from being a medical doctor to a Biotech Leader, and Antonella gives insights and advice to people wanting to become successful in the life science industry. We then delve into AI, where Dr. Chadha provides some super interesting thoughts of how AI will shape Drug Development in the future. Dr. Chadha delivers a combination of advice and stories, including discussion on Regulation vs Drug Development, delegation, Antonella’s experience at TEDx, AI becoming Doctors, Alzheimer’s, the Women’s Brain Foundation, Medical Affairs and Clinical development working hand in hand and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Dr. Antonella S. Chadha LinkedIn: https://www.linkedin.com/in/dr-antonella-santuccione-chadha-6336b41/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 11:00 Regulatory Hurdles in Drug Development 14:23 Academia/ Hospital to Industry 23:20 Longevity: A Complex Landscape 28:49 Communicating with Investors 32:56 AI in the Future 38:33 Embracing Change in Career Transitions 44:37 The Women’s Brain Foundation #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology Hosted on Acast. See acast.com/privacy for more information.
	Ingmar Bruns: Biotech & Pharma Executive, Hematology & Oncology, Leadership	07 Mar 2025	01:00:07
In this episode, our guest is Dr. Ingmar Bruns, M.D., Ph.D., a pioneer in biotech leadership and hematologist/oncologist. Dr Bruns is the Executive VP and CMO at Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We discuss Ingmar's breadth of experience in academia, where he studied medicine at both the Medical University of Vienna, as well as the Universität zu Lübeck, He then spent many years at both the University of Düsseldorf and the Albert Einstein College of Medicine. We discuss a variety of topics including Ingmar’s successes and mistakes, drug development, golden rules for biotechs, as well as fundraising in the life science industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Ingmar Bruns LinkedIn: https://www.linkedin.com/in/ingmar-bruns-9abb5446/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 12:12 Key Accomplishments and Reflections 20:50 Persistence in Drug Development 27:52 Identifying Differentiators in Biotechs 38:00 Communicating with Investors 53:17 Traits of Effective Leadership #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Hematology Hosted on Acast. See acast.com/privacy for more information.
	Christophe Giot: Clinical Cardiologist, Transitioning to Industry & AI in Pharma	28 Feb 2025	00:23:11
In this episode, our episode is Dr. Christophe Giot, a highly accomplished global executive with a foundation as a clinical cardiologist and extensive experience in Clinical and Medical Affairs across diverse therapeutic areas including cardiology (interventional cardiology, structural heart), vascular diseases, interventional oncology, urology, immunology, and rare diseases. Dr. Giot is the CMO and VP Clinical Affairs at Affluent Medical, and attended Université libre de Bruxelles to study Cardiology and become a MD. We discuss how Christophe kick-started his career in the Life Science Industry, before transitioning to Pharma, as well as the key achievements and milestones he made along the way. Dr. Christophe Giot delivers a combination of stories and insights, including discussion on soft skills, communicating with investors, team building, AI in Pharma, the power of networking, onboarding, and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Cristophe Giot LinkedIn: https://www.linkedin.com/in/christophegiot/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 08:03 Transitioning to Industry 14:27 Communicating with Stakeholders 16:36 The Role of AI in Pharma 19:19 Hiring and Onboarding Best Practices #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Cardiology Hosted on Acast. See acast.com/privacy for more information.
	Michael Tusche: Biotech Leadership, Wall Street Investment & AI-Driven Drug Development	21 Feb 2025	00:46:54
In this Episode, our guest is Dr. Michael Tusche, Ph.D., M.B.A, a visionary biotech leader and seasoned investor in the space. Dr. Tusche is also the CEO of 3io Therapeutics, a biotechnology company focused on the development and commercialization of the next generation of viral immunotherapies for cancer. Dr. Tusche is also the Co-Founder and current Board Director at Nirsum Labs, a biotechnology company inventing and developing new medications for opioid use disorder (OUD). We discuss how Michael began his career, from his academia spanning a number of years at the University of Victoria as well as the University of Toronto, to then moving into industry. We then move into a discussion on investing into biotechs, and Dr. Tusche provides insight on how to become a successful biotech leader, with interesting stories and optimisation tips. Dr. Tusche reveals an amazing blend of experiences and advice, featuring discussions of early investment, oncology, micromanagement, addiction, ChatGPT, and obesity. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Micheal Tusche LinkedIn: https://www.linkedin.com/in/vcbiotechceo/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 08:12 Investing In & Leading Biotech Companies 14:44 Differentiators in Biotech Success 24:42 Trends in Biotechs 36:45 Building Optimised Teams in Biotechs 45:06 Quick-fire Round #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology Hosted on Acast. See acast.com/privacy for more information.
	Juergen Reess: Clinical Neurologist, Founding a Biotech & Leadership	14 Mar 2025	00:28:03
In this episode, we sit down with Dr. Juergen Reess, a Board-Certified Neurologist with an incredible career spanning over 20 years in corporate and drug development leadership roles at Boehringer Ingelheim. After an extensive career in big pharma, Juergen transitioned into the world of biotech, where he now plays a pivotal role in shaping the future of medicine. Juergen is the Founder & CEO of MoglingBio Inc, an innovative company in the longevity space, pioneering novel pharmacological approaches to rejuvenate old stem cells, a field with immense potential. As well as this, Juergen is also the Fractional CMO of SciRhom, a Munich-based clinical-stage biotech tackling autoimmune diseases with iRhom2-targeting therapies, where they have just secured a €63M Series A funding round to propel their groundbreaking work. In this insightful conversation, we explore, how Juergen kick-started his career in life sciences, how he kept his career "fresh" in a big pharma setting by taking on new challenges, the challenges and adaptions from transitioning from big pharma to biotech, lessons from founding and funding his own biotech ventures, what "Longevity" really means in the biotech world, how he adapts across various therapeutic areas and much more. This episode is packed with valuable insights for anyone in life sciences, whether you're a scientist, entrepreneur, investor, or industry leader. Don't miss this inspiring discussion on innovation, adaptability, and leadership in biotech! Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Juergen Reess LinkedIn: https://www.linkedin.com/in/juergen-reess-b443468/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 10:23 Shifting to Biotech 16:13 Founding a Biotech 21:15 Communicating with Investors 24:41 AI in Life Sciences #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Neurology Hosted on Acast. See acast.com/privacy for more information.
	Brian Kim: Innovation & AI in Dermatology & Immunology	25 Apr 2025	00:55:18
In this episode, we sit down with Dr. Brian Kim, a true trailblazer at the cutting edge of science and medicine: Co-Founder at Alys Pharmaceuticals, a biopharmaceutical company with an innovation focus on immuno-dermatology, redefining how we understand chronic itch and skin inflammation. Brian is also the Director of the Mark Lebwohl Center for Neuroinflammation and Sensation and the Allen Discovery Center for Neuroimmune Interactions. Sol and Clara Kest Professor and Vice Chair of Research in Dermatology at Icahn School of Medicine at Mount Sinai. Nearly two decades of experience spanning dermatology, immunology, allergy and neuroscience. Internationally recognised for unlocking the mysteries of itch biology, opening doors to entirely new therapeutic approaches. Previously the Co-Founder of Nuogen Pharma and now on the scientific advisory board for Attovia Therapeutics and Triveni Bio. Brian is also an advisor for Septerna - helping to translate scientific insights into next-generation therapies. Recent keynote speaker at the prestigious Friedman Brain Institute’s Neuroscience Retreat, as well as plenary talks across both allergy and dermatology like the American Academy of Allergy, Asthma, and Immunology (AAAAI) Presidential Plenary Session (2/23/2024) and the Marion B. Sulzberger, MD Memorial Award and Lectureship at the American Academy of Dermatology March of 2024 - proving how his work resonates across disciplines. In this episode, we discuss everything from Innovation & AI in dermatology to Leadership in Academia vs Industry. Brian also reveals the reason Dermatology is securing so much funding in 2025. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Brian Kim Co-Founder At Alys Pharmaceuticals LinkedIn: https://www.linkedin.com/in/brian-s-kim-4605662/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Innovation & AI 11:08 Communication & Motivation 23:58 Leadership in Industry VS Academia 35:32 Why Dermatology Secures Funding 49:29 Quickfire Questions #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology #Immunology Hosted on Acast. See acast.com/privacy for more information.
	Frank Watanabe: Dermatology - Self Improvement, Growth & Leadership	15 May 2025	00:40:06
In this episode, we sit down with Dr. Frank Watanabe, a titan of biotech and pharma, and leader shaping the future of medicine: CEO of Arcutis Biotherapeutics, one of the few commercial stage Dermatology focused Biopharma companies; leading them from startup to IPO to commercial success. 25+ years in biotech and pharma with expertise across of various Therapeutic areas. Proven leader in life sciences, known for building and scaling companies from early-stage to FDA approval - with leadership forged from time spent in the U.S. Navy. Former roles at Kythera, Lilly Amgen, and Allergan - driving strategy, R&D, and game-changing product launches. Champion of innovation, access, and purpose-driven leadership across the biopharma ecosystem In this episode, we discuss everything from How Frank built Arcutis, motivation and Self-Improvement that is grounded from his experience in the Navy, revealing the key to success as a leader in the industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Frank Watanabe President, CEO At Arcutis LinkedIn: https://www.linkedin.com/in/frank-watanabe-419711/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings + Arcutis 05:01 Leadership & Growth 20:52 Motivation & Self Improvement 27:40 Personality Traits To Succeed In Pharma 33:30 What’s Next For Arcutis #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	Volker Koscielny: Functionality and Success Behaviours in Leadership	06 May 2025	00:26:38
In this episode, we sit down with Dr. Volker Koscielny, a distinguished figure in the pharmaceutical industry, with a wealth of experience and a forward thinking approach to medical innovation: CMO at Almirall, a global pharmaceutical company specialising in medical dermatology, dedicated to developing innovative treatments for skin diseases. 20+ years of experience in dermatology, bridging between R&D, business development, marketing, and sales. Recognised globally for his commitment to understanding patient needs and demonstrating the real-world value of medicines. Former roles at Celgene, GlaxoSmithKline, Pfizer, Servier and Boehringer Ingelheim, leaving Volker with the experience to lead and scale cross-functional teams ensures the seamless integration of regulatory, clinical, and commercial strategies. Volker recently contributed to Almirall’s 15th annual Skin Academy, a conference that brings together dermatologists from across Europe to discuss advancements in inflammatory skin diseases and patient well-being. In this episode, we discuss the future of dermatology, Volker’s insights from industry roundtables, and the key experiences and achievements that shaped his success in the field. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Volker Koscielny Chief Medical Officer at Almirall LinkedIn: https://www.linkedin.com/in/volker-koscielny/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Leadership In Life Sciences 10:40 Potential In Dermatology 16:21 Functionality As A Leader 22:40 Achievements & Wrapping Up #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	Bernardo Cervantes: Microbial Therapeutics & Scaling Leadership	22 May 2025	00:30:31
In this episode, we sit down with Dr. Bernardo Cervantes, leading the charge in microbiome science, with a mix of experience and insights: Bernardo is the Co-Founder and COO of Concerto Biosciences, a biotech pioneering the development of microbial consortia-based therapeutics. With a robust background in microbial engineering, Bernardo has dedicated his career to studying microbial interactions and microbiome health. His expertise spans sythetic biology and metabolic engineering. Bernardo is internationally recognised for his contributions to microbiome science, particularly in translating complex microbial ecology into practical applications. His work at Concerto Biosciences has positioned him as a thought leader in developing next-generation microbial therapeutics. Prior to co-founding Concerto Biosciences, Bernardo earned his PhD in Microbiology from the Massachusetts Institute of Technology (MIT). Concerto has been active at major scientific conferences, including the 2024 BIO International Convention, where Concerto Biosciences was featured in the NIH Innovation Zone. In this episode, we discuss the future of microbiome sciences, Bernardo’s key learnings throughout his career, how he’s adapted his leadership as one of three Co-Founders, management, a great opportunity within the market and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Dr. Bernardo Cervantes Chief Operations Officer at Concerto Biosciences LinkedIn: https://www.linkedin.com/in/bernacularbio/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings & Concerto Biosciences 10:16 Concerto Biosciences - Key Learnings 15:26 Team Building & Culture 23:52 Quickfire Questions #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	Tomoko Maeda-Chubachi: Dermatology Leader, Fractional CMO	05 Jun 2025	00:24:09
In this episode, we sit down with Dr. Tomoko Maeda-Chubachi - a global leader in dermatology drug development and biotech innovation: Dr. Maeda-Chubachi serves as fractional Chief Medical Officer at various startups focusing on dermatology indications. 20+ years experience in the pharmaceutical industry, Dr. Maeda-Chubachi has held senior roles at major companies like Pfizer, Eli Lilly, and GSK. Her expertise spans the entire drug development process, from early-phase trials to regulatory approvals. Tomoko has multiple notable achievements, she led the FDA approval of Zelsuvmi, helped secure a $250M deal for Vtama, and was named one of 2023’s top CMOs to watch. Dr. Maeda-Chubachi is a sought-after speaker, having presented at events like the Dermatology Drug Development Summit and the Japan Biotech Panel. She is also an active member of Women In Bio, receiving the Long Tenure Active Member Award from the RTP chapter. In this episode, we discuss a range of topics, including her career beginnings, challenges that come with drug development, leadership in biotech, key achievements and much more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Tomoko Maeda-Chubachi CMO at Kalm Therapeutics + Boardroom Ready at Women in Bio LinkedIn: https://www.linkedin.com/in/tomoko-maeda-chubachi/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 06:23 Drug Development 08:59 Leadership 13:58 Achievements + Fractional CMO #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	Nick Reder: TechBio Leadership, 3D AI Spatial Biology	29 May 2025	00:31:04
In this episode, we sit down with Nicholas Reder, who’s pushing the boundaries in AI-driven spatial tissue analysis, with a mix of experience and insights: Nick is the Founder & CEO at Alpenglow Biosciences, pioneers in AI-powered 3D spatial biology that transforms how we see and understand tissue biopsies. 10+ years in translational research, with degrees in biochem, epidemiology, and medicine – plus a residency and fellowship in pathology at the University of Washington. Co-developed a groundbreaking open-top light-sheet microscope – now the core of Alpenglow’s tech. Nick is a major conference speaker at AACR, SID, PMWC, NextGen Omics, BIO International and more, and has won the Castleman Award - the highest global honour for pathologists under 40. In this episode, we discuss a range of topics including Alpenglow’s current success and what the future looks like, hiring talent within techbios, as well and leadership challenges within the computational biology space. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Nicholas Reder Founder + CEO at Alpenglow Biosciences LinkedIn: https://www.linkedin.com/in/nicholas-reder-210a578b/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings & Alpenglow 04:54 AI & Hiring Talent 14:58 Challenges / Key Triggers When Hiring 19:36 Alpenglow Biosciences 24:14 What’s Next - Quickfire Round #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	Needle in a Haystack Antibody Unlocking A Fundamental Pathway in Disease Biology: Bhaskar Srivastava	18 Aug 2025	00:41:24
If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for. We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene. In this episode, Bhaskar dives deep into: · How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology. · What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference. · Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials. · Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis. · Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science. 🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Bhaskar Srivastava CMO at Triveni Bio LinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 15:44 Success & Growth in Biotech 28:43 Investing in Biotech 34:23 The Future of Dermatology & Triveni Bio #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	Mara Aspinall: The Former CEO Now Funding the Genomics Revolution	07 Aug 2025	00:44:48
If you care about the future of genomics, diagnostics, and biotech investing, you can’t miss this episode. We’re joined by Mara Aspinall, Partner at Illumina Ventures, a trailblazer with over 30 years of leadership in diagnostics and eight years in venture capital funding groundbreaking genomics companies. In this episode, Mara reveals: The next wave of diagnostics, from liquid biopsies to home testing and new AI-driven tools. Hard-won lessons from leading Genzyme Genetics, Roche Tissue Diagnostics, and building her own startup. Insider tips for founders on pitching, choosing the right investors, and building winning teams. A glimpse into where genomics is heading in the next decade - from neurodegenerative disease detection to early metabolic disease diagnostics. With her unmatched experience as an operator, educator, and investor, Mara brings clarity, energy, and vision to a fast-changing field. This conversation is packed with takeaways for founders, investors, and anyone fascinated by the future of healthcare. 🎧 Tune in now for a masterclass in diagnostics, genomics, and venture capital from one of the industry’s most influential voices. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Mara Aspinall Partner At Illumina Ventures LinkedIn: https://www.linkedin.com/in/mara-aspinall-6688142/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 04:10 Current Diagnostic Trends 20:48 The Founder Investor Fit 25:37 Genetics & Genomics 29:06 Mara Aspinall 39:31 Neurodegenerative Disease #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	Building Biotech in Saudi Arabia: An Investor’s View	31 Jul 2025	00:40:16
To anyone interested in life science VC investment – you need to watch this. In this episode, we’re joined by Dr. Sascha Berger, a biotech investment director based in Saudi Arabia and a very experienced life science investor globally. With nearly two decades in the industry, he’s seen breakthroughs, pivots, and billion-dollar transactions. He reveals: Saudi Arabia’s high-stakes plan to become a global biotech superpower by 2040 - and why it could disrupt the industry as we know it. The real role of a VC beyond the money - how top investors become game-changing partners for founders. Raw stories from the front lines - startups on the brink of collapse that fought back to success. No-fluff advice for first-time founders on building the right team and surviving the brutal biotech rollercoaster. A global insider’s view on the next wave of innovation - from Boston’s biotech streets to the Middle East’s rising hubs. This is one of our most unfiltered and insightful episodes yet - a must-watch for founders, investors, or anyone who wants to see where life sciences is really heading. 🎧 Tune in now to hear how a leading investor is driving biotech’s next era. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Sascha Berger Saudi Arabia Biotech Investor LinkedIn: https://www.linkedin.com/in/sasber/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 08:04 Investing in Success 26:13 Saudi Arabia - The Future 36:29 How to Secure Investment #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.
	How Maxion’s KnotBody® Platform Is Changing the Way We Treat the ‘Undruggable’	02 Sep 2025	00:32:42
Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership. In this episode, we cover: How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseases Why conviction, speed, and storytelling are non-negotiable in translational drug development Lessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnerships What investors really look for - and how Maxion secured a competitive Series A in a tough market How to hire and scale for scientific excellence without losing agility or collaboration Tune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Arndt Schottelius CEO at Maxion Theraprutics LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 06:46 Translational Science 08:55 Lessons in Biotech Leadership 25:23 Maxion - Culture and Roundup #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	From Clinic to Billion-Dollar Breakthroughs: Christopher Morabito’s Journey in Biotech	26 Aug 2025	00:47:43
If you want to understand what it really takes to build and lead a successful biotech, this episode is for you. Dr. Christopher Morabito, Chief Medical Officer at Astria Therapeutics, joins us to share hard-won lessons from 25 years in rare disease, oncology, and immunology. But this isn’t a career retrospective - it’s a deep dive into the mindset, strategies, and leadership habits that drive biotech success. In this episode, Chris reveals: How to make tough go/no-go decisions when the data isn’t clear. The leadership traits that keep teams aligned, motivated, and resilient in high-pressure environments. Why clarity of purpose matters more than anything else in a biotech’s mission. How to navigate the tension between scientific ambition and commercial reality. The patterns he’s seen across programs that make it from idea to approval. Chris distills decades of experience into practical, actionable advice for founders, executives, and investors - making this one of the most insightful conversations we’ve had yet. 🎧 Tune in for a rare, candid look at biotech leadership from someone who’s been on the front lines of game-changing therapies. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Christopher Morabito CMO at Astria Therapeutics LinkedIn: https://www.linkedin.com/in/chrismorabito/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 13:40 Moving Into Biotech 23:34 Leading in Biotech 28:41 Patients First 38:23 Lessons & Legacy #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	Normunity's Breakthrough Cancer Drug the World Hasn't Seen Before	09 Sep 2025	00:39:47
Two of the most influential minds in immuno-oncology walk into a biotech… and build something that could change everything. Dr. Rachel Humphrey (CEO) and Dr. Melinda Merchant (CMO) of Normunity are two of the most seasoned and respected leaders in oncology drug development, with a combined 45+ years of experience across big pharma, biotech, and translational science. Rachel led the development of Yervoy® (ipilimumab) at BMS, Imfinzi® (durvalumab) at AstraZeneca, and Nexavar® (sorafenib) at Bayer, before holding CMO roles at Black Diamond, Mirati, and CytomX. Melinda, an immunologist and dual board-certified pediatric oncologist, spent a decade leading clinical studies at NIH and Memorial Sloan Kettering, running early trials of ipilimumab, nivolumab, and novel cell therapies before moving to industry and leading clinical development efforts of multiple investigational new drugs. Together, they now lead Normunity, where they’re pioneering a bold new therapeutic category: immune normalizers - designed to unlock immune resistance and open up new frontiers in cancer treatment.In this episode, we cover: - How Normunity is redefining immuno-oncology with its first-in-class T-cell engager - What it takes to build scientific teams that challenge each other - and still move fast - Lessons from launching Yervoy, Imfinzi, Tazverik, and other breakthrough therapies - Why biotech culture needs both humility and ego to succeed - What’s next as Normunity prepares to enter the clinic with NRM-823 If you're a life sciences leader, founder, or investor - this conversation is essential listening. Tap in to hear what it really takes to build, lead, and scale science that matters. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Rachel Humphrey CEO at Normunity LinkedIn: https://www.linkedin.com/in/rachel-w-humphrey-md-116b211b/ Melinda Merchant CMO at Normunity LinkedIn: https://www.linkedin.com/in/melinda-merchant-7b496a/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 16:58 Traits of a Drug Developer 19:53 Leadership in Biotech 27:28 Story Behind Normunity 30:23 Normunity Culture 32:28 Mindsets in Translational Science 36:33 Personal Life #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	Is Nuclear Medicine Becoming Next Big Breakthrough in Oncology Treatment? Danielle Meyrick	19 Sep 2025	00:34:42
If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes. This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover: Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today. From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style. What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures. The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum. What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector. If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Danielle Meyrick Co-Founder + Director At EPIC Theranostiocs LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 06:12 Nuclear Medicine 09:26 Characteristics of a Good Drug Developer 14:13 Future of Radiotheranostics 20:05 Approaching Challenges 26:52 Advice 29:25 Motivations 30:56 Greatest Achievements #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.
	Building a High-Impact Biotech Investment Engine - Clare Terlouw	18 Nov 2025	00:39:49
What does it take to shape a high-impact biotech investment portfolio - and do it under a medical charity mandate? This week we sit down with Clare Terlouw, Head of LifeArc Ventures, whose 20+ year career spans investment banking, biotech company building, and leading venture teams focused on health innovation. With a unique perspective at the intersection of science, capital, and patient impact, Clare shares a candid and optimistic view of the evolving biotech landscape in the UK and beyond. In this episode, Clare covers: - LifeArc Ventures’ mission: how a medical charity is driving returns while staying true to a patient-first vision. - Investing and scaling biotech: from early inflection points to Series B and beyond, what great companies get right. - Biotech in the UK: challenges in the current funding environment, the talent surge, and why optimism still holds. - Tech-enabled drug discovery: how AI, computational biology, and new business models are shaping investment priorities. - Clare's leadership lens: her personal drive, how she evaluates opportunity, and the power of staying focused on patient outcomes. Be sure to check out this episode if you're interested in the future of biotech investing, the rise of tech-enabled therapeutics, and how one venture leader is backing science that matters. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Clare Terlouw Managing Partner at Life Arc LinkedIn: https://www.linkedin.com/in/clare-terlouw-b608aa17/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Life Arc - Investments + Impact 09:44 Investing in and Growing a Company 17:52 Biotech in the UK 26:18 Tech Enabled Drug Discovery 32:57 Clare Terlouw Hosted on Acast. See acast.com/privacy for more information.
	CEO of LEO Pharma Reveals Their IPO Strategy: Christophe Bourdon	25 Nov 2025	00:35:02
A once-in-a-century transformation, and the leader driving it. This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history. With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams. In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering: Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity. The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner. Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent. Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners. Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness. This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core. Be sure to check out this episode - one of our most important conversations to date. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Christophe Bourdon CEO of LEO Pharma LinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 LEO’S Recent Achievements 06:58 Shaping a Modern LEO Pharma 16:30 LEO Pharma’s IPO Journey 25:39 Christophe’s Leadership Hosted on Acast. See acast.com/privacy for more information.
	How To Get Investment from Joey Mason \| 25 Years In Life Sciences VC	09 Dec 2025	00:51:37
25 years of life sciences venture experience in one episode. This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale. In this episode, Joey covers: Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms. He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem. Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders. A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures. Joey shares exactly what he looks for in a pitch, and what turns him off instantly. Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation. Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale. Follow ARTO! LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Lawrence Rose Co-Founder + Talent Solutions Director at @ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Joey Mason Venture Advisor @Sofinnova Venture Partner @Claret Capital Partners LinkedIn: https://www.linkedin.com/in/joey-mason/ Timestamps 01:09 Joey’s Career 05:14 Investment approaches 19:17 Most successful investment 28:20 Leadership 32:46 How to pitch to Joey Mason 42:21 Future plans #LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy Hosted on Acast. See acast.com/privacy for more information.
	How Syncona built a $1Billion Dollar NAV Portfolio - Roel Bulthuis	02 Dec 2025	00:45:29
🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business? 🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited. Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up. Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time. ⭐️ Syncona has an impressive portfolio including, Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics. 🚀 In this episode, Roel dives into: - What defines a Syncona company and its unique model - Key lessons learned from both successes and setbacks - How to manage investor involvement without stifling progress - The challenges of leadership transitions within portfolio companies - Syncona’s strategic commitment to the European market - What drives Roel personally and what he enjoys most about his role Check out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝 Follow ARTO! LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Lawrence Rose Co-Founder + Talent Solutions Director at @ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Role Bulthuis Managing Partner @Syncona LinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/ Timestamps: 01:10 What makes up a Syncona company? 11:25 What were the main lessons learnt from previous failures/successes? 15:06 Managing investor involvement & preventing counter productivity. 22:14 The issues with exchanging leadership. 31:07 Commitment to the European Market. 42:20 What Roel enjoys about his job. Hosted on Acast. See acast.com/privacy for more information.
	How NodThera’s NLRP3 Marks A New Era for Obesity Treatment	18 Dec 2025	00:41:56
Cardio-metabolic diseases are the world’s biggest killer. But what if the next generation of treatments could change everything? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, SGLT2, PCSK9 and now the emerging NLRP3 inhibitor class. His work spans companies such as Novo Nordisk, Amgen, Boehringer Ingelheim and his move into biotech with NodThera marks a shift from big-Pharma leadership into next-wave therapeutic development. In this episode, Jyothis covers: - How NodThera is shaping the future of metabolic and inflammatory disease treatment. - A look at the mindset and challenges behind leading in a high-stakes biotech environment. - Why the right investors often play a critical mentorship role in biotech growth. - Exploring why endocrinology remains underfunded and overlooked in biotech circles. - How he previously worked with Eli Lilly (led by David Ricks), contributing to their efforts in the cardiometabolic space. - Reflections on personal legacy, long-term impact, and how to get in touch. If you’re interested in cardio-metabolic innovation, GLP-1 evolution, biotech strategy or leadership at the cutting edge of science, this episode is worth your time. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Jyothis George CMO at NodThera LinkedIn: https://www.linkedin.com/in/jyothisgeorge/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 01:40 NodThera's Role in Future Endocrinology 10:48 Leadership in Biotech 21:05 Investment and Mentorship 30:58 Endocrinology's Underinvestment 38:13 Jyothis George: Legacy & Contact Hosted on Acast. See acast.com/privacy for more information.
	Nikhil Thatte On Investing In Best In Class Biotech and Medtech Companies	06 Jan 2026	00:45:03
This episode is a masterclass in how world-class life sciences investors think about risk, conviction, and real patient impact. This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America. In this conversation, Nikhil shares how Lumira Ventures has built a top-quartile VC track record over multiple market cycles, investing across therapeutic areas including oncology, gene editing, gene therapy, immunology, cardiometabolic disease, and medical devices. He also reflects on his journey helping scale globally impactful healthcare companies while staying grounded in patient outcomes. In this episode, Nikhil covers: • How Lumira Ventures evaluates investment opportunities in today’s biotech market, including why clinical data, valuation discipline, and a clear path to liquidity now matter more than ever (08:38) • Lessons from Lumira’s major exit successes, including Histosonics and Endotronix, and what made these companies stand out from an investor perspective, with insights into leadership, timing, and execution alongside Mike Blue at Histosonics (02:33) • What truly differentiates exceptional founders and management teams, with real examples of conviction moments backing leaders such as Joanna Stanicka at Axonis and Jade Doucet-Martineau at Puzzle Med (22:08) • Why Canada punches above its weight in life sciences innovation, the structural challenges holding the ecosystem back, and what must change to retain value domestically, including reflections on Canadian success stories discussed throughout the episode (17:40) • The vision behind the Cancer Breakthrough Fund, Lumira’s partnership with the Terry Fox Foundation, and how this model brings new capital, clinical expertise, and impact-driven investors into oncology innovation (31:08) If you want a rare, honest look inside how top life sciences VCs assess opportunity, leadership, and long-term value creation, this is an episode you don’t want to miss. Follow ARTO: https://linktr.ee/arto_talent Nikhil Thatte LinkedIn: https://www.linkedin.com/in/nikhil-thatte-72372333/ Lawrence Rose Director at ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction to Nikhil Thatte and Lumira Ventures 02:33 Major exits including Histosonics and Endotronix 05:30 Fund V and what drives LP conviction today 08:38 How Lumira evaluates deals in the current biotech market 17:40 Canada’s competitive advantages and ecosystem challenges 22:08 Backing exceptional founders and leadership teams 31:08 The Cancer Breakthrough Fund and Terry Fox Foundation partnership 37:00 Technologies and trends shaping the next 5–10 years 41:16 Patient impact and what ultimately motivates long-term investing #LeadingBeyondTheLab #ARTOTalent #LifeSciences #BiotechVC #Medtech #VentureCapital #CanadianInnovation Hosted on Acast. See acast.com/privacy for more information.
	Parkinson’s Breakthrough Could Be Just Around the Corner \| BlueRock Therapeutics	29 Jan 2026	00:28:30
From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options? This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development. A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry. In this episode, Amit covers: • How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09) • What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29) • The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58) • Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37) • Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00) If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time. Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders. Follow ARTO: https://linktr.ee/arto_talent Amit Rakhit LinkedIn: https://www.linkedin.com/in/amit-rakhit/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction and background 01:09 Cell therapy and BlueRock Therapeutics’ mission 03:29 Leadership, credibility, and execution 04:58 CEO vs CMO roles in biotech 06:37 Authenticity, inclusion, and culture 09:24 What separates successful biotechs 12:00 Physician scientists transitioning into industry 18:34 Career-defining moments and resilience 22:38 The future of cell therapy and emerging modalities 24:32 AI in drug discovery and clinical development 26:26 Closing thoughts and where to connect #LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment Hosted on Acast. See acast.com/privacy for more information.
	How Smart Capital Is Shaping the Future of Biotech - Jonathan Tobin	20 Jan 2026	00:43:46
97% of our viewers don't realise they aren't followed, please double check, thank you! What does it really take to back and build world-class biotech companies from idea to FDA approval? This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital. With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US. In this episode Jonathan covers: - How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK. - Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades. - Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes. - Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds. - How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds. - Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle. Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech. To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform. Hosted on Acast. See acast.com/privacy for more information.
	Is AI About to Collapse the Cost of Healthcare — Or Is This Another Tech Bubble? \| Edward Kliphuis	03 Feb 2026	00:41:05
If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble? This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms. With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide. In this episode, Edward covers: - What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics. - Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs. - Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point - He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities. - Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures. - Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures. From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next. To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below! Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Youtube: https://www.youtube.com/@life_sciences Website: https://arto-talent.com Edward Kliphuis Partner at Sofinnova Partners LinkedIn: https://www.linkedin.com/in/ekliphuis/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Sofinnovas Partner's Investments 17:41 The US Pharma "Bubble" & AI 28:02 Investing in the Right CEO / Company Hosted on Acast. See acast.com/privacy for more information.
	Will the Drug Work? Engineering a New Future for Oncology - BioCortex	03 Mar 2026	00:57:44
90% of our listeners don't realise they aren't subscribed - please check! What if we could predict whether a drug will work, before it ever reaches a patient? This week, in another episode of Leading Beyond the Lab, we host a co-guest episode featuring Nik Sharma, CEO & Co-Founder of BioCortex, a trained neurologist with years of experience spanning clinical medicine, ALS research, academia (Cambridge, NIH) and more. And Muhannad Alomari, CTO & Co-Founder, with over a decade of experience spanning aerospace engineering, AI leadership and physics-based systems modelling. In this episode, the duo covers: Why bacteria inside tumours may explain clinical trial variability, how “in silico bridge trials” could reshape oncology development, and how BioCortex plans to translate that science into commercial inflection points, global licensing models, and long-term value creation without taking traditional pipeline risk. From partnerships with CD BioPharma, they explain how global clinical strategy, particularly leveraging innovation and trial infrastructure emerging from China, is reshaping how oncology assets are advanced and positioned for global success. They also discuss investor backing from Edward Kliphuis from Sofinnova, Hussein Kanji from Hoxton Ventures and Draper Associates, and how capital discipline combined with deep-tech engineering principles (inspired by Rolls-Royce and even NASA) is shaping a new model for oncology drug development. They also reflect on visiting leading oncology centres in China alongside HSBC and AstraZeneca, highlighting the sheer scale and speed of patient recruitment, momentum that was clearly visible in multiple back-to-back presentations at ASCO, signalling a structural shift in global cancer innovation. This is a conversation about speed, probability, biology, engineering, and ultimately, time. Because for patients, time is everything. To listen to (or watch) the full episode, search “Leading Beyond the Lab BioCorteX” on wherever you get your podcasts, or click on the first link in the comments below. Hosted on Acast. See acast.com/privacy for more information.
	A Single Injection set to Eliminate Cancer? CEO of Candel Therapeutics - Paul Peter Tak	24 Feb 2026	01:01:01
What if a single injection could teach the immune system to eliminate cancer, and keep it away? This week, in another episode of Leading Beyond the Lab, Lawrence Rose sits down with Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, one of the most quietly compelling stories in cancer immunotherapy today. With over 30 years of experience spanning academic medicine, clinical immunology, rheumatology, oncology, and global pharmaceutical leadership, Paul Peter brings a rare clinician-scientist perspective to biotech leadership. Prior to Candel, he served as Chief Immunology Officer and Global Head of Development at GSK (led by Luke Miels) , where he helped shape immunology and oncology strategy at scale. Paul Peter is also founder and previous chair of the dept of clinical immunology and rheumatology at Amsterdam UMC. In this episode, Paul Peter covers: - The mission behind Candel Therapeutics and why viral immunotherapy represents a fundamentally new modality, shifting the goal from helping patients live longer with cancer to helping them live without cancer. - Why Candel’s lead programs (including CAN-2409) are gaining serious scientific credibility, supported by leaders such as Nobel laureate James P. Allison and the "father of CAR-T cell therapy" Carl June, and how this external validation is changing industry and investor perception. - Lessons from past paradigm shifts in medicine, drawing on his early academic work at Leiden University, where once-dismissed antibody therapies later became standard of care, a parallel to today’s scepticism around viral immunotherapy. - How leadership, culture, and decision-making drive biotech success, shaped by his experience building teams in academia, transforming R&D at GSK, and learning large-scale leadership from mentors like Lord Patrick Vallance. - Why flexible operating models matter in biotech, including Candel’s approach to commercialisation through partners such as IDEA Pharma (led by Mike Rea) and Globe Life Sciences (Jonathon Mitchell), and cautionary lessons from companies like Oncorus and Replimune. Be sure to check out this episode to hear how Paul-Peter Tak is helping redefine what’s possible in cancer immunotherapy - and what it takes to lead beyond the lab. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Youtube: https://www.youtube.com/@life_sciences Website: https://arto-talent.com Paul Peter Tak CEO at Candel Therapeutics LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 01:50 Candel's Mission 19:51 The US Promising Future for Candel 35:44 Culture at Candel 40:44 Paul Peter's Motivations as CEO Hosted on Acast. See acast.com/privacy for more information.
	I Built A Billion-Dollar Company, Lost It All... Then Built Another 5 - Robert Wessman	28 Apr 2026	01:23:58
What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms. This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of experience spanning global pharmaceuticals, generics, biosimilars and serial entrepreneurship. In this episode, Robert Wessman covers: (01:12) Why biologics dominate the future of pharmaceuticals and the urgent need to expand access through biosimilars, with treatment costs reaching up to $100,000 per patient annually (04:10) Building seven companies including six unicorns, and scaling a global generics business across 80+ countries with over 16,500 employees (12:32) The seven-pillar framework behind building high-performance culture, including vision setting, team alignment and execution discipline (18:14) The importance of timing in biotech, and how starting too early or too late in biosimilars can determine success or failure (38:16) Strategic foresight in action, from anticipating regulatory changes to building one of the largest biosimilars pipelines with over 30 products This conversation offers a clear, experience-backed perspective on scaling in life sciences, building resilient organisations and making high-impact decisions in complex markets. If you are working in biotech, pharma or leadership, this episode provides practical insights worth applying. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Robert Wessman LinkedIn: https://www.linkedin.com/in/robert-wessman/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction 00:46 The global cost challenge of biologics 01:12 Market dynamics and future of biosimilars 03:11 Origins of building multiple pharma companies 04:10 Scaling Actavis into a global leader 05:22 Repeatable frameworks for building companies 06:53 Execution, culture and operational excellence 10:01 Building Alvotech in Iceland 11:10 Hiring globally and building culture 12:32 The seven pillars of high-performance culture 15:28 Execution and accountability at scale 17:03 Scaling rapidly while maintaining culture 18:14 Timing the biosimilars market 19:27 Fundraising and early-stage selling 22:07 Building partnerships and licensing strategy 24:21 Manufacturing strategy and infrastructure 25:49 Business development and commercial model 27:11 Building global supply chains 28:23 Transitioning leadership roles 30:29 Evolution of CEO skillsets 32:03 AI and the future of work in pharma 34:03 Hiring for high-performance teams 36:33 Managing risk and operational challenges 37:07 Reducing development costs through foresight 38:16 Scaling pipeline strategy 40:25 Patent challenges and market barriers 42:19 Anticipating market shifts in biologics 44:11 Navigating setbacks and industry challenges 45:26 Market dynamics and global pricing pressures 47:08 Why Iceland as a strategic base 50:47 Attracting global talent to Iceland 53:09 Capital markets and disciplined growth 54:40 Risks of overfunding 55:04 Personal story and adversity 58:19 Near-death cycling accident 01:00:30 Recovery and resilience 01:05:55 Impact on mindset and life perspective #LeadingBeyondTheLab #ARTOTalent #Biotech #Pharmaceuticals #Biosimilars #LifeSciences #Leadership Hosted on Acast. See acast.com/privacy for more information.
	AI Discovering Medicines Humans Could Never Find: James Field - LabGenius Therapeutics	20 Apr 2026	00:47:02
AI is beginning to uncover medicines that humans alone could never design. This week on another episode of Leading Beyond the Lab, we host James Field, CEO and Founder of LabGenius Therapeutics, a company pioneering the use of machine learning, robotics, and synthetic biology to engineer the next generation of therapeutic antibodies. With over a decade of experience spanning AI-driven drug discovery, protein engineering, and synthetic biology, James founded LabGenius Therapeutics to rethink how biologic medicines are discovered. In this episode, James discusses: - The founding story of LabGenius Therapeutics and how its AI-guided experimentation platform is transforming antibody engineering. - The companies backing by leading investors including Kindred Capital (Leila Zegna), Lux Capital, Obvious Ventures, M Ventures, and Octopus Ventures, and is guided by industry leaders such as Edwin Moses, the company’s Chairman and a veteran biotech executive. - LabGenius Therapeutics' collaboration with Sanofi, and how partnerships between biotech startups and global pharma companies are helping translate AI-designed antibodies into real therapeutic pipelines. - The importance of global scientific conferences such as European Society for Medical Oncology, where breakthroughs in oncology and biologics are shaping the future of therapeutic development. - The mentors and inspirations that shaped his journey into biotech, from his university lecturers at Imperial College London to industry leaders like Edwin Moses, who now serves as Chairman of LabGenius Therapeutics and has played a key role in guiding the company’s growth. If you're interested in AI-driven drug discovery, biotech entrepreneurship, and the future of medicine, this episode is one you won’t want to miss. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Dr. James Field LinkedIn: https://www.linkedin.com/in/james-field-7518a05b/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 02:40 Rewriting the Rules of Drug Discovery 16:21 Scaling Innovation 37:29 AI, Motivation & Purpose Hosted on Acast. See acast.com/privacy for more information.
	AI Is About to Simulate Human Biology - Bioptimus	05 May 2026	00:56:29
95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold. In this episode, Jean-Philippe covers: • Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development. • How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction. • Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine. • How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT) • What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments. A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading. Be sure to check out the full episode. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Jean-Philippe Vert CEO at Bioptimus LinkedIn: https://www.linkedin.com/in/jean-philippe-vert/ Lawrence Rose Talent Solutions Director at ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps 00:00 Introduction and vision for AI as a universal simulator of biology 01:41 Introducing Jean-Philippe Vert and @Bioptimus 02:27 What Bioptimus is doing differently in AI biology 07:46 AI decision systems and improving clinical development 12:52 Early disease detection and predictive healthcare 15:28 Why Jean-Philippe left @Google 19:21 Building and sourcing biological data at scale 22:19 Partnerships and foundation models 28:04 Lessons from big tech 33:23 Defensibility in AI biology 37:09 Building interdisciplinary teams and culture 39:28 AI in healthcare, hype versus infrastructure 41:20 What AI means for doctors 43:10 What may define lasting AI-biology companies 45:05 Challenges of building Bioptimus 48:13 Prioritisation and deciding where to focus 51:33 Mentorship, leadership and building teams 53:02 Communicating vision to boards and investors 55:33 What success looks like in ten years #LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine Hosted on Acast. See acast.com/privacy for more information.
	We’re Developing The Next Generation Of Parkinson’s Therapies, And Here's How - Brenig Therapeutics	18 May 2026	01:04:28
95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. This week on Leading Beyond The Lab, Lawrence Rose sat down with Megan McGill, CEO of Brenig Therapeutics, with years of experience spanning biotech leadership, strategy, clinical medicine, management consulting and neuroscience research. In this episode, Megan covers: • Why Brenig Therapeutics is targeting neuroinflammation and Parkinson’s disease through LRRK2 and NLRP3 inhibitors, and how the company is positioning itself within the rapidly evolving neurodegenerative disease landscape. • How AI and machine learning are being used across medicinal chemistry and drug development at Brenig through investment from Torrey Pines, OrbiMed, New Enterprise Associates, BioGeneration Ventures, to optimise brain penetration, selectivity and safety profiles simultaneously. • Why Megan believes an MD and PhD background is critical in biotech leadership, combining a deep understanding of disease biology with a real-world understanding of patients and unmet medical needs. • The realities of building a career in medicine, biotech and leadership while raising children as a single mother, and the leadership lessons around empathy, patience and resilience that came from that experience. • Why neuroscience investment remains significantly underfunded despite the growing global burden of neurodegenerative disease, and what needs to change across biotech, pharma and venture capital to accelerate progress in CNS innovation. • Lawrence and Megan also discuss organisations and companies including Eli Lilly and Company, McKinsey & Company, BridgeBio Pharma and the Michael J. Fox Foundation. Be sure to check out the full episode to hear Megan’s perspective on the future of neuroscience, biotech leadership and the evolving role of AI across drug development. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Megan McGill CEO at Brenig Therapeutics LinkedIn: https://www.linkedin.com/in/mcgillmegan/ Lawrence Rose Consulting Director at ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction 02:21 Megan’s background across medicine, biotech and neuroscience 03:03 Joining Brenig Therapeutics and the company’s pipeline 04:16 LRRK2 and NLRP3 inhibitors in Parkinson’s disease 05:23 The growing neuroinflammation landscape 06:51 Phase 1 clinical trial milestones and biomarkers 07:23 Why Brenig chose Parkinson’s disease 10:14 AI medicinal chemistry and machine learning in drug discovery 12:08 How AI is changing biotech operations and strategy 14:20 Brenig’s Series B strategy and upcoming milestones 15:57 Building efficient biotech teams and scaling operations 17:30 Leadership inspiration and high-performing teams 18:46 The advantages of being an MD and PhD in biotech leadership 21:16 Commercial partnerships and pharma collaboration strategy 23:08 Digital biomarkers, diagnostics and wearable technology 28:06 Balancing medicine, biotech leadership and motherhood 33:30 Mentorship, McKinsey and learning commercial strategy 37:00 Leadership communication and simplifying complexity 38:23 What defines elite biotech teams and company culture 40:40 Brenig’s board, investors and strategic support 43:16 Building a culture of excellence in a virtual biotech company 46:13 The future of neuroscience and neurodegenerative disease 50:25 Clinical trial recruitment and patient engagement 52:34 The Biotech CEO Sisterhood and women in biotech leadership 56:17 Diversity, leadership and representation in biotech Hosted on Acast. See acast.com/privacy for more information.
	The Next Generation of Autoimmune Therapies? Inside SciRhom’s IRhom2 Platform	01 Jun 2026	00:56:53
95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. Can targeting IRhom2 unlock a new generation of autoimmune disease treatments? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jan Poth and Jens Ruhe of SciRhom, discussing a new therapeutic approach focused on IRhom2 and TACE inhibition in autoimmune disease. The conversation explored the scientific origins of the company, lessons from failed inflammatory pathway inhibitors, and the challenge of building a biotech platform in one of the toughest funding environments in recent years. In this episode, Jan Poth and Jens Ruhe cover: • Why previous TACE inhibitors failed and how targeting IRhom2 could offer a more selective approach to inflammatory diseases • The scientific breakthrough that convinced the founding team IRhom2 could be druggable despite industry skepticism at the time (Carl Blobel, Hospital for Special Surgery) • Why combining multiple inflammatory pathways may be necessary to move beyond the efficacy ceiling seen with TNF and IL-6 inhibitors • How the company secured an oversubscribed Series A after speaking with more than 150 investors over two years, with backing from Wellington Partners, Hadean Ventures, Kurma Partners, Andera Partners, MIG Capital, Bain Capital, and HTGF • The roadmap for S878, expectations for the upcoming Phase I trial in rheumatoid arthritis patients, and the long-term ambition to become the defining company in IRhom2 therapeutics. This episode offers a detailed look into modern biotech company building, translational immunology, and the realities of advancing a first-in-class therapeutic platform from concept to clinic. If you are interested in autoimmune disease innovation, antibody development, biotech financing, or platform company strategy, this conversation is well worth your time. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Jan Poth & Jens Ruhe CEO & COO at SciRhom LinkedIn: https://www.linkedin.com/in/jan-poth-a79424136/ LinkedIn: https://www.linkedin.com/in/jens-ruhe/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction to immune system complexity and inflammatory disease challenges 01:38 Podcast introduction and overview of SciRhom’s approach 02:30 The origins of targeting IRhom2 and TACE 05:20 The founding of SciRhom and early scientific conviction 06:39 Discovering IRhom2 surface accessibility with Carl Blobel 08:26 Combining inflammatory pathway inhibition 12:14 Complexity of the immune system and autoimmune disease treatment 14:20 Why single pathway inhibitors reach an efficacy ceiling 18:15 Raising a successful Series A in a difficult biotech market 20:23 Overview of lead candidate S878 and upcoming Phase I trial 24:15 Fundraising challenges and early investor support from HTGF 31:47 Key milestones and expectations for Phase I readouts 34:22 Building a pipeline around IRhom2 biology 35:24 Balancing speed, capital efficiency, and scientific rigor 39:55 Founder dynamics and collaborative decision-making 43:12 Bringing commercial development expertise into biotech strategy 49:11 Balancing patient impact with commercial success 49:45 Long-term vision for SciRhom and IRhom2 therapeutics 52:30 AI, technology, and reducing drug development costs 55:11 Shared mission and improving outcomes for autoimmune disease patients 56:34 Closing remarks #LeadingBeyondTheLab #ARTOTalent #Biotech #Immunology #AutoimmuneDisease #DrugDevelopment #AntibodyTherapeutics #RheumatoidArthritis #LifeSciences Hosted on Acast. See acast.com/privacy for more information.

About us Privacy Policy